These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 32200189)

  • 1. Novel therapeutic approaches in chronic myeloid leukemia.
    Özgür Yurttaş N; Eşkazan AE
    Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
    Eide CA; Zabriskie MS; Savage Stevens SL; Antelope O; Vellore NA; Than H; Schultz AR; Clair P; Bowler AD; Pomicter AD; Yan D; Senina AV; Qiang W; Kelley TW; Szankasi P; Heinrich MC; Tyner JW; Rea D; Cayuela JM; Kim DW; Tognon CE; O'Hare T; Druker BJ; Deininger MW
    Cancer Cell; 2019 Oct; 36(4):431-443.e5. PubMed ID: 31543464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Third-line therapy for chronic myeloid leukemia: current status and future directions.
    Cortes J; Lang F
    J Hematol Oncol; 2021 Mar; 14(1):44. PubMed ID: 33736651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.
    Wylie AA; Schoepfer J; Jahnke W; Cowan-Jacob SW; Loo A; Furet P; Marzinzik AL; Pelle X; Donovan J; Zhu W; Buonamici S; Hassan AQ; Lombardo F; Iyer V; Palmer M; Berellini G; Dodd S; Thohan S; Bitter H; Branford S; Ross DM; Hughes TP; Petruzzelli L; Vanasse KG; Warmuth M; Hofmann F; Keen NJ; Sellers WR
    Nature; 2017 Mar; 543(7647):733-737. PubMed ID: 28329763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Lee H; Basso IN; Kim DDH
    Int J Hematol; 2021 May; 113(5):632-641. PubMed ID: 33772728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
    Yang K; Fu LW
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and Resistance to BCR-ABL1-Targeted Therapies.
    Braun TP; Eide CA; Druker BJ
    Cancer Cell; 2020 Apr; 37(4):530-542. PubMed ID: 32289275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interferon-alpha revival in CML.
    Talpaz M; Mercer J; Hehlmann R
    Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.